A5060304924- RNA Interference and Gene Delivery
- Streptococcal Infections and Treatments
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Biochemical and Structural Characterization
- Advanced biosensing and bioanalysis techniques
- Glycosylation and Glycoproteins Research
- vaccines and immunoinformatics approaches
- Virus-based gene therapy research
- Antimicrobial Peptides and Activities
- Neonatal and Maternal Infections
- Antimicrobial Resistance in Staphylococcus
- Immune Response and Inflammation
- Peptidase Inhibition and Analysis
- Pneumonia and Respiratory Infections
- Phase Equilibria and Thermodynamics
- MicroRNA in disease regulation
- Bacterial Infections and Vaccines
- Toxin Mechanisms and Immunotoxins
- Botanical Research and Chemistry
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- Transgenic Plants and Applications
- Bacteriophages and microbial interactions
- Advanced Drug Delivery Systems
The University of Queensland
2016-2025
Indian Institute of Technology Delhi
2024
GTx (United States)
2019
Brisbane School of Theology
2016
Rockefeller University
2010
QIMR Berghofer Medical Research Institute
2006-2008
Group A Streptococcus (GAS) infections account for an estimated 500,000 deaths every year. This bacterial pathogen is responsible a variety of mild and life-threatening the triggering chronic autoimmune sequelae. Pharyngitis caused by group (GAS), but not asymptomatic GAS carriage, prerequisite acute rheumatic fever (ARF). Repeated bouts ARF may trigger heart disease (RHD), major cause failure stroke accounting 275,000 annually. vaccine that prevents pharyngitis would markedly reduce...
Group A Streptococcus (GAS) is an important human pathogen responsible for both superficial infections and invasive diseases. Autoimmune sequelae may occur upon repeated infection. For this reason, development of a vaccine against GAS represents major challenge, since certain components trigger autoimmunity. We formulated three combination vaccines containing the following: (i) streptolysin O (SLO), interleukin 8 (IL-8) protease (Streptococcus pyogenes cell envelope proteinase [SpyCEP]),...
Subunit vaccines offer a means to produce safer, more defined compared traditional whole microorganism approaches. antigens, however, exhibit weak immunity, which is normally overcome through coadministration with adjuvants. Enhanced vaccine properties (e.g., improved potency) can be obtained by linking antigen and adjuvant, as observed for synthetic peptide antigens Toll-like receptor 2 (TLR2) ligands. As few protective have been reported, protein we sought extend the utility of this...
The development of 16 self-adjuvanting group A streptococcal vaccine candidates, composed (i) a universal helper T-cell epitope (P25), (ii) target GAS B-cell (J14), and (iii) lipid moiety, is described. Systemic J14-specific IgG antibodies were detected following subcutaneous immunization BALB/c (H-2d) mice with each construct without the need for an additional adjuvant. effect changing order P25, J14, moiety attachment or incorporation P25 J14 into lipid-core peptide system on antibody...
ADP-ribosylation is an important post-translational modification involved in processes including cellular replication, DNA repair, and cell death. Despite these roles, the functions of ADP-ribosylation, particular mono-ADP-ribosylation, remain poorly understood. The development a technique to generate large amounts site-specific, ADP-ribosylated peptides would provide useful tool for deconvoluting biochemical roles ADP-ribosylation. Here we demonstrate that synthetic histone H2B tail...
To explore four-arm star poly(t-butyl)acrylate (P(t)BA)-peptide and linear P(t)BA-peptide conjugates as a vaccine-delivery system against Group A Streptococcus.P(t)BA nanoparticles bearing J14 peptide epitopes were prepared via alkyne-azide 1,3-dipolar cycloaddition 'click' reaction. The conjugated products self-assembled into small or large nanoparticles. These nanoparticle vaccine candidates evaluated in vivo J14-specific antibody titers assessed.Mice vaccinated with the able to produce...
This study aimed to develop and optimize chemistries produce alkyne-modified glucagon-like peptide-1(7–36)-amide (GLP-1(7–36)-NH2) libraries, which could be rapidly efficiently conjugated other components screened identify compounds with the best drug delivery properties, as potential treatments for type 2 diabetes or obesity. For this purpose, Lys26 (K26) side-chain, amino (N)- carboxy (C)-termini of a dipeptidyl peptidase 4 (DPPIV)-resistant GLP-1 sequence (GLP-1(7–36;A8G)-NH2), were...
Aim: Utilize lipopeptide vaccine delivery system to develop a candidate against Group A Streptococcus. Materials & methods: Lipopeptides synthesized by solid-phase peptide synthesis-bearing carboxyl (C)-terminal and amino (N)-terminal Streptococcus epitopes. Nanoparticles formed were evaluated in vivo. Results: Immune responses induced mice without additional adjuvant. We demonstrated for the first time that incorporation of C-terminal epitope significantly enhanced N-terminal...
Vaccination has a proven record as one of the most effective medical approaches to prevent spread infectious diseases. Traditional vaccine involve administration whole killed or weakened microorganisms stimulate protective immune responses. Such deliver many microbial components, some which contribute immunity, and assist in guiding type response that is elicited. Despite their impeccable record, these have failed yield vaccines for important organisms. This prompted move towards more...
Glucagon-like peptide-1 GLP-1 is a gut-derived peptide secreted from pancreatic β-cells that reduces blood glucose levels and body weight; however, native (GLP-1(7–36)-NH2 GLP-1(7–37)) have short in vivo circulation half-lives (∼2 min) due to proteolytic degradation rapid renal clearance its low molecular weight (MW; 3297.7 Da). This study aimed improve the stability delivery properties of glucagon-like (GLP-1) through modifications form nanostructures. For this purpose, N- (NtG) C-terminal...